Quantcast
Last updated on April 16, 2014 at 4:43 EDT

Latest GlySure Limited Stories

2014-01-07 08:30:10

OXFORD, England, January 7, 2014 /PRNewswire/ -- GlySure reaches major milestone in delivering continuous blood glucose monitoring (CBGM) technology to the healthcare marketplace GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, will present the results of its European regulatory trial at the OneMedForum 2014 conference on January 13, 2014, in San Francisco. OneMedForum 2014 will be the first...

2013-10-30 08:31:28

OXFORD, England, October 30, 2013 /PRNewswire/ -- GlySure making important progress in delivering continuous blood glucose monitoring (CBGM) technology to the healthcare marketplace GlySure Limited today announced that it has completed patient enrollment for the multicenter CE Mark trial of its in-hospital continuous blood glucose monitoring (CBGM) system. The trial, led by Principal Investigator Dr. Krishna Prasad, comprised 30 post surgery...

2013-10-01 08:30:38

GlySure recognized by BIG for unparalleled progress in delivering continuous blood glucose monitoring technology to the healthcare marketplace OXFORD, England, October 1, 2013 /PRNewswire/ -- GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, today announced that it has won two major awards in the 2013 BIG (Business Intelligence Group) Awards for Business. BIG has selected GlySure as Small Business of the Year and it also won...

2013-09-25 08:29:09

McQuillan leads efforts to secure CE mark for GlySure's continuous blood glucose monitoring technology OXFORD, England, September 25, 2013 /PRNewswire/ -- GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, today announced the appointment of Justine McQuillan as its European Director of Clinical Affairs. In this newly established position, McQuillan is leading European clinical regulatory trials of GlySure's CBGM technology, which the...

2013-08-28 08:27:28

Primary investigator presents results at the World Federation of Societies of Intensive and Critical Care Medicine (WFSICCM) Congress OXFORD, England, August 28, 2013 /PRNewswire/ -- GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, today announced that a study demonstrating the effectiveness of its technology in continuously measuring blood glucose levels in post-surgical cardiac surgery patients will be presented at the World...

2013-06-26 08:30:29

MedTech veteran to support GlySure's preparation for commercialization of its continuous blood glucose monitoring technology OXFORD, England, June 26, 2013 /PRNewswire/ -- GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, today announced the appointment of William Moffitt as Executive Chairman. Moffitt has more than 35 years of experience in the medical diagnostics and device industry. He takes on the Executive Chairman role at...

2013-03-26 08:29:35

At Biovision Investor Conference and IN Medical Device 360 Dublin, GlySure will disclose cardiac surgery ICU trial findings and progress toward CE mark OXFORD, England, March 26, 2013 /PRNewswire/ -- GlySure Limited, developer of in-hospital continuous blood glucose monitoring (CBGM) systems, will present the results of its cardiac surgery intensive care trial and plans for CE mark testing at two leading MedTech conferences this spring. GlySure CEO Christopher Jones will...

2013-03-05 08:28:33

Achievement marks key progress toward European regulatory trials OXFORD, England, March 5, 2013 /PRNewswire/ -- GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, today announced that it has achieved ISO 13485 certification, the global standard for the requirements of a quality management system for the design, manufacture and distribution of medical devices. By establishing a quality management system that meets international regulatory and...

2012-11-28 08:29:06

ABINGDON, England, November 28, 2012 /PRNewswire/ -- GlySure Limited, developer of in-hospital continuous blood glucose monitoring systems, has completed the second close of its Series C financing round for a total of $13.6 million. GlySure will use this funding to complete clinical trials in support of U.S. and European regulatory clearance. Series C investors included Amadeus Capital Partners, Chester Investments, Delta Partners, Morningside Ventures and Frank Bonsal,...

2012-09-25 02:25:06

ABINGDON, England, September 25, 2012 /PRNewswire/ -- GlySure Limited, developer of in-hospital continuous glucose monitoring (CGM) systems, will update the industry on its progress toward U.S. and European regulatory trials at two leading MedTech conferences this fall. GlySure CEO Christopher Jones will speak at the AdvaMed 2012 MedTech Conference on October 2 in Boston, and at the Medical Devices Summit Europe on November 14 in Dublin. Tight Glycemic Control (TGC) in...